Effectiveness and safety of different hemodialysis modalities: A review

Journal of Nephrology

Volumn 20, Issue 5, 2007, Pages 525-542

  Lema, Leonor Varela ^a   Raviña, Alberto Ruano ^a,b,c  

^a Galician Agency for Health Technology Assessment   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c Agencia de Evaluacion de Tecnologias Sanitarias de Galicia   (Spain)

Author keywords

Chronic renal failure; Dialysis; End stage renal disease; Hemodiafiltration; Hemodialysis; High efficiency; High flux; Low flux; Renal dialysis

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CELLULOSE DERIVATIVE; CUPROPHANE; HEMOGLOBIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; POLYACRYLONITRILE; POLYSULFONE; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANEMIA; CARDIOVASCULAR RISK; CLINICAL TRIAL; COCHRANE LIBRARY; DEATH; EMBASE; FOLLOW UP; HEMODIAFILTRATION; HEMODIALYSIS; HEMOFILTRATION; HOSPITALIZATION; HUMAN; INDIVIDUALIZATION; INTERMETHOD COMPARISON; KIDNEY FAILURE; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDLINE; METHODOLOGY; MORBIDITY; MORTALITY; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT SAFETY; PATIENT SELECTION; QUALITY OF LIFE; RESEARCH SUBJECT; REVIEW; RISK FACTOR; CHRONIC KIDNEY FAILURE; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

HEMODIAFILTRATION; HUMANS; KIDNEY FAILURE, CHRONIC; PATIENT SELECTION; QUALITY OF LIFE; RENAL DIALYSIS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 38149108130     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Varela Lema L, Ruano Raviña A. Efectividad y seguridad de las diferentes variantes de hemodialisis y hemodiafiltranión. Santiago de Compostela: Servicio Galego de Saúde. Axencia de Avaliación de Tecnoloxías Sanitarias de Galicia, avalia-t. 2006. Report No. Serie de Avaliación de Tecnoloxías. Informe de Avaliación; INF 2005/03.
2. National Kidney Foundation. K/DOQI clinical practice guidelines for hemodialysis adequacy, 2000. Am J Kidney Dis 2001; 37 (Suppl 1): S7-64.
3. ERA-EDTA Registry. ERA-EDTA Registry annual report. Amsterdam (The Netherlands): Academic Medical Center 2003.
4. Shinaberger JH. Quantitation of dialysis: Historical perspective. Semin Dial 2001; 14: 238-45.
5. Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, Clark W, Levy AS, Leypoldt JK, Ornt DB, Rocco MV, Schulman G, Schwab S, Teehan B, Eknoyan G; for the HEMO Study Group. Effects of high-flux hemodialysis on clinical outcomes: Results of the HEMO Study. J Am Soc Nephrol 2003; 14: 3251-63.
6. Allon M, Depner TA, Radeva M, Bailey J, Beddhu S, Butterly D, Coyne DW, Gassman JJ, Kaufman AM, Kaysen GA, Lewis JA, Schwab SJ; for the HEMO Study Group. Impact of dialysis dose and membrane on infection-related hospitalization and death: Results of the HEMO Study. J Am Soc Nephrol 2003; 14: 1863-70.
7. Eknoyan G, Beck G, Cheung AK, Daugirdas MD, Greene T, Kusek JW. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-9.
8. Woods HF, Nandakumar M. Improved outcome for haemodialysis patients treated with high-flux membranes. Nephrol Dial Transplant 2000; 15 (Suppl 1): S36-42.
9. Hornberger JC, Chernew M, Petersen J, Garber AM. A multivariate analysis of mortality and hospital admissions with high-flux dialysis. J Am Soc Nephrol 1992; 3: 1227-37.
10. Churchill DN, Bird DR, Taylor DW, Beecroft ML, Gorman J, Wallace JE. Effect of high-flux hemodialysis on quality of life and neuropsychological function in chronic hemodialysis patients. Am J Nephrol 1992; 12: 412-8.
11. Gordon SM, Oettinger CW, Bland LA, Oliver JC, Arduino MJ, Aguero SM, McAllister SK, Favero MS, Jarvis WR. Pyrogenic reactions in patients receiving conventional, high-efficiency, or high-flux hemodialysis treatments with bicarbonate dialysate containing high concentrations of bacteria and endotoxin. J Am Soc Nephrol 1992; 2: 1436-44.
12. Pegues DA, Oettinger CW, Bland LA, Oliver JC, Arduino MJ, Aguero SM, McAllister SK, Gordon SM, Favero MS, Jarvis WR. A prospective study of pyrogenic reactions in hemodialysis patients using bicarbonate dialysis fluids filtered to remove bacteria and endotoxin. J Am Soc Nephrol 1992; 3: 1002-7.
13. Opatrny Jr K, Reischig T, Vienken J, Eiselt J, Vit L, Opatrna S, Sefrna F, Racek J, Brown GS. Does treatment modality have an impact on anemia in patients with chronic renal failure? Effect of low- and high-flux biocompatible dialysis. Artif Organs 2002; 26: 181-8.
14. Merello Godino JI, Rentero R, Orlandini G, Marcelli D, Ronco C. Results from EuCliDR (European Clinical Dialysis Database): impact of shifting treatment modality. Int J Artif Organs 2002; 25: 1049-60.
15. Ottosson P, Attman PO, Knight C, Samuelsson O, Weiss L, Alaupovic P. Do high-flux dialysis membranes affect renal dyslipidemia? ASAIO J 2001; 47: 229-34.
16. House AA, Wells GA, Donnelly JG, Nadler SP, Hebert PC. Randomized trial of high-flux vs low-flux haemodialysis: Effects on homocysteine and lipids. Nephrol Dial Transplant 2000; 15: 1029-34.
17. Locatelli F, Andrulli S, Pecchin F, Pedrini L, Agliata S, Lucchi L, Farina M, Vincenzo LM, Grassi C, Borghi M, Redaelli B, Conte F, Ratto G, Cabiddu G, Grossi C, Roberto M. Effect of high-flux dialysis on the anaemia of haemodialysis patients. Nephrol Dial Transplant 2000; 15: 1399-409.
18. Marcus RG, Cohl E, Uribard J. Middle molecule clearance does not influence protein intake in hemodialysis patients. Am J Kidney Dis 1998; 31: 491-4.
19. Fischbane S, Bucala R, Pereira BJ, Founds H, Vlassara H. Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia. Kidney Int 1997; 52: 1645-50.
20. Churchill DN, Taylor DW, Tomlinson CW, Beecroft ML, Gorman J, Stanton E. Effect of high-flux hemodialysis on cardiac structure and function among patients with end-stage renal failure. Nephron 1993; 65: 573-7.
21. Kuchle C, Fricke H, Held E, Schiffl H. High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis. Am J Nephrol 1996; 16: 484-8.
22. Schiffl H, D'Agostini B, Held E. Removal of beta 2-microglobulin by hemodialysis and hemofiltration: A four year follow up. Biomater Artif Cells Immobilization Biotechnol 1992; 20: 1223-32.
23. Locatelli F, Mastrangelo F, Redaelli B, Ronco C, Marcelli D, La Greca G, Orlandini G; the Italian Cooperative Dialysis Study Group. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. Kidney Int 1996; 50: 1293-302.
24. Mastrangelo F, Alfonso L, Rizzelli S, Aprile M, Sandri L. Anemia in high-efficiency dialysis. Nephrol Dial Transplant 1991; 6 (Suppl 2): S116-21.
25. Kerr PB, Argiles A, Flavier JL, Canaud B, Mion CM. Comparison of hemodialysis and hemodiafiltration: A long-term longitudinal study. Kidney Int 1992; 41: 1035-40.
26. Malberti F, Surian M, Farina M, Vitelli E, Mandolfo S, Guri L, De Petri GC, Castellani A. Effect of hemodialysis and hemodiafiltration on uremic neuropathy. Blood Purif 1991; 9: 285-95.
27. Basile C, Giordano R, Montanaro A, De Maio P, De Padova F, Marangi AL, Semeraro A. Effect of acetate-free biofiltration on the anaemia of haemodialysis patients: A prospective cross-over study. Nephrol Dial Transplant 2001; 16: 1914-9.
28. Eiselt J, Racek J, Opatrny K Jr. The effect of hemodialysis and acetate-free biofiltration on anemia. Int J Artif Organs 2000; 23: 173-80.
29. Verzetti G, Navino C, Bolzani R, Galli G, Panzetta G. Acetate-free biofiltration versus bicarbonate haemodialysis in the treatment of patients with diabetic nephropathy: A cross-over multicentric study. Nephrol Dial Transplant 1998; 13: 955-61.
30. Panichi V, Bianchi AM, Cirami C, Parrini M, Andreini B, Finato V, Soldani I, Casarcsa L, Palla R. Paired filtration dialysis (PFD): Biocompatibility, dialytic efficiency and clinical tolerance in a long-term multicenter trial. J Nephrol 1994; 8: 155-61.
31. Lin CL, Huang CC, Yu CC, Yang HY, Chuang FR, Yang CW. Reduction of advanced glycation end product levels by online hemodiafiltration in long-term hemodialysis patients. Am J Kidney Dis 2003; 42: 524-31.
32. Bonforte G, Grillo P, Zerbi S, Surian M. Improvement of anemia in hemodialysis patients treated by hemodiafiltration with high-volume on-line-prepared substitution fluid. Blood Purif 2002; 20: 357-63.
33. Lin CL, Huang CC, Yu CC, Wu CH, Chang CT, Hsu HH, Hsu PY, Yang CW. Improved iron utilization and reduced erythropoietin resistance by on-line hemodiafiltration. Blood Purif 2002; 20: 349-56.
34. Lin CL, Huang CC, Chang CT, Wu MS, Hung CC, Chien CC, Yang CW. Clinical improvement by increased frequency of on-line hemodialfiltration. Ren Fail 2001; 23: 193-206.
35. Ward RA, Schmidt B, Hullin J, Hillebrand GF, Samtleben W. A comparison of on-line hemodiafiltration and high-flux hemodialysis: A prospective clinical study. J Am Soc Nephrol 2000; 11: 2344-50.
36. Wizemann V, Lotz C, Techert F, Uthoff S. On-line haemodiafiltration versus low-flux haemodialysis: A prospective randomized study. Nephrol Dial Transplant 2000; 15 (Suppl 1): S43-8.
37. Panichi V, Migliori M, De Pietro S, Metelli MR, Taccola D, Perez R, Palla R, Rindi P, Cristofani R, Tetra C. Plasma C-reactive protein in hemodialysis patients: A cross-sectional, longitudinal clinical survey. Blood Purif 2000; 18: 30-6.
38. Panichi V, Tetta C, Rindi P, Palla R, Lonnemann G. Plasma C-reactive protein is linked to backfiltration associated interleukin-6 production. ASAIO J 1998; 44: M415-7.
39. Maduell F, Del Pozo C, Garcia H, Sanchez L, Hdez Jaras J, Albero MD, Calvo C, Torregrosa I, Navarro V. Change from conventional haemodiafiltration to on-line haemodiafiltration. Nephrol Dial Transplant 1999; 14: 1202-7.
40. Maduell F, Del Pozo C, Garcia H, Sanchez L, Hernandez Jaras J, Albero MD, Calvo C, Torregrosa I, Navarro V. Change from conventional hemodiafiltration (HDF) to on-line HDF: One year experience. Nefrologia 1998; 18: 308-15.
41. Vaslaki L, Berta K, Major L, Weber V, Weber C, Wojke R, Passlick-Deetjen J, Falkenhagen D. On-line hemodiafiltration does not influence inflammatory response in end-stage renal disease patients: Results from a multicenter crossover study. Artif Organs 2005; 29: 406-12.
42. Lowrie EG, Huang WH, Lew NL. Death risk predictors among peritoneal dialysis and hemodialysis patients: A preliminary comparison. Am J Kidney Dis 1995; 26: 220-8.
43. Sanz-Moreno C. Técnicas de hemodiálisis. In Lorenzo Sellarés V, Torres Ramírez A, Hernández Marrero D, Ayus JC Eds. Manual de nefrología clínica, diálisis y transplante renal. Madrid (Spain): Harcourt Brace de España 1998; 447-60.
44. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 (Suppl 3): S112-9.
45. Covic A, Gusbeth Tatomir P, Glodsmith JA. The challenge of cardiovascular risk factors in end-stage renal disease. J Nephrol 2003; 16: 476-86.
46. Rattazzi M, Puato M, Faggin E, Bertiplagia B, Grego F, Pauletto P. New markers of accelerated atherosclerosis in end-stage renal disease. J Nephrol 2003; 16: 11-20.
47. Locatelli F, Marcelli D, Conte F, Limido A, Malberti F, Spotti D. Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. Kidney Int 1999; 55: 286-93.
48. Ministerio de Sanidad y Consumo-Instituto de Salud de Carlos III. Agencia de Evaluación de Tecnologías Sanitarias (AETS). Evaluación de los diferentes tipos de de membranas de hemodiálisis. Madrid (Spain): AETS-Instituto de Salud Carlos III 1996.
49. Maduell F. Dialisis adecuada. Nefrologia 2002;22:111-34.
50. Port FK, Wolfe RA, Hulbert-Shearon TE, Daugirdas JT, Agodoa L, Jones C. Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: Results from the USRDS dialysis morbidity and mortality study. Am J Kidney Dis 2001;37:276-86.
51. Ruano A, Pérez-Ríos M, Branas P, Figueiras A. Limitaciones metodológicas en la realización de estudios que comparan técnicas de hemodiálisis. Nefrologia 2003; 23: 390-3.
52. Elinder CG, Jones AL, Briggs JD. Improved survival in renal replacement therapy in Europe between 1975 and 1992: An ERA-EDTA Registry study. Nephrol Dial Transplant 1999; 14: 2351-6.
53. US Renal Data System. USRD 2003 annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD (USA): National Institutes of Health, National Institute of Diabetis and Digestive Kidney Disease 2003.